Short answer
Viridian Therapeutics, Inc.\DE (VRDN) filed an 8-K current report with the SEC on May 5, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.2). Reg FD disclosure furnished under Item 7.01, not filed under Exchange Act Section 18.
Viridian Therapeutics, Inc.\DE 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Reg FD disclosure furnished under Item 7.01, not filed under Exchange Act Section 18
- No substantive company update included in the provided text
- Disclosure generally excluded from incorporation by reference into other filings
Item EX-99.1 · Exhibit EX-99.2
- REVEAL-2 met FDA and EMA primary endpoints, validating elegrobart in chronic TED with p < 0.0001
- Proptosis responder rates 50% Q4W and 54% Q8W versus 15% placebo at week 24
- Q4W achieved 61% diplopia response versus 38% placebo, supporting broader symptom benefit
- Favorable safety profile: 91% treatment completion, no treatment-related serious adverse events, low hearing impairment
- BLA submission remains targeted for Q1 2027, with potential at-home autoinjector positioning in chronic TED
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Viridian Therapeutics, Inc.\DE 8-K filings
Get the next VRDN 8-K as it lands
Follow VRDN for push alerts, or ask the research agent what this filing means.